VivoSeq
Oncology

Advanced Breast Cancer

18

Pipeline Programs↗

10

Active Trials↗

9

Companies Involved↗

Advanced Breast Cancer is an emerging landscape with 18 programs across 9 companies. The most active players are AstraZeneca, Roche, Beijing Biostar Pharmaceuticals Co., Ltd.. 2 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

22/100

Mech. Concentration

27/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

3 programs

Phase 3Roche logo

Roche

3 programs

Phase 3B

Beijing Biostar Pharmaceuticals Co., Ltd.

2 programs

Phase 3Eli Lilly logo

Eli Lilly

2 programs

Phase 3Pfizer logo

Pfizer

3 programs

Phase 3F

Fresenius Kabi Oncology Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

15 of 18 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody211%Antibody–drug conjugate16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 90% of 20 pipeline programs.

Analysis

Trial Status

12

clinical trials

Recruiting5 · 42%
Not yet recruiting3 · 25%
Completed2 · 17%
Active, not recruiting2 · 17%

Clinical Trials

Trial Activity

12 trials

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06710990·32 enrolled
A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07427394·24 enrolled
Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)
Recruiting·GGeneplus-Beijing Co. Ltd.·N/A·NCT07681323·400 enrolled
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Recruiting·Roche logoRoche·Phase 3·NCT06065748·1,050 enrolled
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06380751·500 enrolled
A Phase II Open-label, 2-Part, Multi-center Study of BYL719 (Alpelisib) in Combination With Fulvestrant for Men and Postmenopausal Women With PIK3CA Mutation Hormone Receptor (HR) Positive, HER2-negative, Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment in Japan
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT04524000·24 enrolled
Advanced Breast Cancer Patients Treated With Oral Vinorelbine: a Prospective and Retrospective, Observational Study - VINOREAL
Active, not recruiting·PPierre Fabre Medicament·N/A·NCT06500494·368 enrolled
A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)
Not yet recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT07683754·200 enrolled
A Randomized,Controlled Phase III Study on Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
Not yet recruiting·BBeijing Biostar Pharmaceuticals Co., Ltd.·Phase 3·NCT07684456·308 enrolled
A Prospective, Multicenter Clinical Study on the Efficacy Correlation of Deruxtepruzumab Treatment for Advanced Breast Cancer With Low/Ultra-low HER2 Expression, Guided by Peripheral Blood CTCs/CTECs Combined With Serum HER2 Detection
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT07670182·100 enrolled
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
Completed·BBeijing Biostar Pharmaceuticals Co., Ltd.·Phase 1·NCT05052437·16 enrolled
ALPelisib INdia Safety STudy (ALPINIST): A Phase IV, Prospective, Multicenter, Open-label, Non-comparative, Interventional Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR Positive, HER2-negative, Advanced Breast Cancer (aBC) With a PIK3CA Mutation, Whose Disease Has Progressed on or After Endocrine Based Treatment.
Completed·Novartis logoNovartis·Approved·NCT05631795·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)